Compare BHM & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHM | ATNM |
|---|---|---|
| Founded | 2022 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.5M | 31.4M |
| IPO Year | 2022 | 2013 |
| Metric | BHM | ATNM |
|---|---|---|
| Price | $8.05 | $1.13 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.60 |
| AVG Volume (30 Days) | 2.0K | ★ 102.2K |
| Earning Date | 01-01-0001 | 11-13-2026 |
| Dividend Yield | ★ 6.27% | N/A |
| EPS Growth | N/A | ★ 14.17 |
| EPS | N/A | ★ 0.71 |
| Revenue | ★ $68,734,000.00 | $90,000.00 |
| Revenue This Year | $1.31 | $19,344.45 |
| Revenue Next Year | $11.18 | N/A |
| P/E Ratio | ★ N/A | $1.49 |
| Revenue Growth | ★ 36.88 | 11.11 |
| 52 Week Low | $7.87 | $0.74 |
| 52 Week High | $13.30 | $1.74 |
| Indicator | BHM | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 51.40 |
| Support Level | N/A | $0.96 |
| Resistance Level | $8.87 | $1.13 |
| Average True Range (ATR) | 0.33 | 0.08 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 22.50 | 58.62 |
Bluerock Homes Trust Inc owns and operates a portfolio of institutional residential properties including single-family homes, build-to-rent communities, and other residential communities located in attractive markets with a focus on the knowledge-economy and high-quality of life growth markets of the Sunbelt and Western United States. The company's principal objective is to generate attractive risk-adjusted returns on investments where it believes it can drive growth in funds from operations and net asset value by acquiring residential units, developing residential communities, and through value-add renovations. The company has two reportable segments, consisting of Residential Communities, which derives maximum revenue; and Scattered Single-family homes.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.